Nancie M. Archin

9.0k total citations · 2 hit papers
86 papers, 5.5k citations indexed

About

Nancie M. Archin is a scholar working on Virology, Infectious Diseases and Immunology. According to data from OpenAlex, Nancie M. Archin has authored 86 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Virology, 62 papers in Infectious Diseases and 28 papers in Immunology. Recurrent topics in Nancie M. Archin's work include HIV Research and Treatment (82 papers), HIV/AIDS drug development and treatment (47 papers) and HIV/AIDS Research and Interventions (42 papers). Nancie M. Archin is often cited by papers focused on HIV Research and Treatment (82 papers), HIV/AIDS drug development and treatment (47 papers) and HIV/AIDS Research and Interventions (42 papers). Nancie M. Archin collaborates with scholars based in United States, South Africa and Canada. Nancie M. Archin's co-authors include David M. Margolis, Ronald J. Bosch, Joseph J. Eron, Daria J. Hazuda, Daniel Parker, Amanda M. Crooks, Amy S. Espeseth, John M. Coffin, JoAnn Kuruc and Kara S. Keedy and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Nancie M. Archin

80 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

2012 878 citations Nancie M. Archin, Abigail Liberty et al. profile →
Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies

2015 298 citations Anna B. Cope, JoAnn D. Kuruc et al. The Journal of Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nancie M. Archin United States	39	4.6k	3.1k	1.7k	1.5k	864	86	5.5k
Cynthia A. Derdeyn United States	35	5.0k 1.1×	3.0k 1.0×	2.2k 1.3×	982 0.7×	1.2k 1.4×	85	5.7k
Mary F. Kearney United States	37	5.7k 1.2×	4.3k 1.4×	1.6k 0.9×	1.3k 0.9×	1.2k 1.4×	104	6.6k
Rémi Fromentin Canada	36	3.4k 0.7×	1.9k 0.6×	1.8k 1.0×	652 0.4×	873 1.0×	69	4.2k
Mathias Lichterfeld United States	45	5.0k 1.1×	2.9k 0.9×	3.8k 2.2×	1.1k 0.7×	1.4k 1.6×	137	7.2k
Jacqueline D. Reeves United States	31	2.9k 0.6×	2.9k 0.9×	1.8k 1.0×	883 0.6×	1.1k 1.2×	62	5.2k
Julianna Lisziewicz United States	31	3.1k 0.7×	2.3k 0.7×	1.2k 0.7×	1.3k 0.9×	754 0.9×	105	4.5k
Monika Hermankova United States	8	4.1k 0.9×	2.8k 0.9×	1.5k 0.9×	588 0.4×	725 0.8×	8	4.5k
Lucy M. Carruth United States	13	4.0k 0.9×	2.7k 0.9×	1.5k 0.9×	505 0.3×	745 0.9×	16	4.3k
Karen Chadwick United States	18	7.8k 1.7×	5.2k 1.7×	3.0k 1.7×	1.0k 0.7×	1.3k 1.6×	33	8.6k
Jesus F. Salazar-Gonzalez United States	20	3.9k 0.8×	2.0k 0.6×	2.1k 1.2×	1.0k 0.7×	1.1k 1.3×	36	5.1k

Countries citing papers authored by Nancie M. Archin

Since Specialization

Citations

This map shows the geographic impact of Nancie M. Archin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancie M. Archin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancie M. Archin more than expected).

Fields of papers citing papers by Nancie M. Archin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancie M. Archin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancie M. Archin. The network helps show where Nancie M. Archin may publish in the future.

Co-authorship network of co-authors of Nancie M. Archin

This figure shows the co-authorship network connecting the top 25 collaborators of Nancie M. Archin. A scholar is included among the top collaborators of Nancie M. Archin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancie M. Archin. Nancie M. Archin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Archin, Nancie M., et al.. (2025). A targeted CRISPR screen identifies ETS1 as a regulator of HIV-1 latency. PLoS Pathogens. 21(4). e1012467–e1012467.

Tyers, Lynn, Brian Richardson, Deelan Doolabh, et al.. (2024). The persistent pool of HIV-1-infected cells is formed episodically during untreated infection. Journal of Virology. 99(2). e0097924–e0097924.

Aouizerat, Bradley E., Ke Xu, Bryan C. Quach, et al.. (2024). Frequent Cocaine Use is Associated With Larger HIV Latent Reservoir Size. JAIDS Journal of Acquired Immune Deficiency Syndromes. 97(2). 156–164. 1 indexed citations

Archin, Nancie M., et al.. (2024). A novel high-throughput microwell outgrowth assay for HIV-infected cells. Journal of Virology. 98(3). e0179823–e0179823. 2 indexed citations

Lee, Sook-Kyung, Yinyan Xu, Joanna Warren, et al.. (2024). Sequence Analysis of Inducible, Replication-Competent Virus Reveals No Evidence of HIV-1 Evolution During Suppressive Antiviral Therapy, Indicating a Lack of Ongoing Viral Replication. Open Forum Infectious Diseases. 11(5). ofae212–ofae212.

Gray, Carley N, Derek H. Janssens, Jennifer Kirchherr, et al.. (2024). Integrator complex subunit 12 knockout overcomes a transcriptional block to HIV latency reversal. eLife. 13. 1 indexed citations

Joseph, Sarah, Melissa-Rose Abrahams, Lynn Tyers, et al.. (2024). The timing of HIV-1 infection of cells that persist on therapy is not strongly influenced by replication competency or cellular tropism of the provirus. PLoS Pathogens. 20(2). e1011974–e1011974. 4 indexed citations

Falcinelli, Shane D., Ellen Van Gulck, Brigitte Allard, et al.. (2024). Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets. Antimicrobial Agents and Chemotherapy. 68(7). e0020124–e0020124. 4 indexed citations

Falcinelli, Shane D., Alicia D. Volkheimer, Lesia Semenova, et al.. (2023). Impact of Cannabis Use on Immune Cell Populations and the Viral Reservoir in People With HIV on Suppressive Antiretroviral Therapy. The Journal of Infectious Diseases. 228(11). 1600–1609. 6 indexed citations

10.

Riou, Catherine, Sarah Joseph, Nancie M. Archin, et al.. (2021). Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. Clinical Infectious Diseases. 73(8). 1528–1531. 8 indexed citations

11.

Gaebler, Christian, Shane D. Falcinelli, Elina Stoffel, et al.. (2020). Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. Journal of Virology. 95(6). 40 indexed citations

12.

Abrahams, Melissa-Rose, Sarah Joseph, Nigel Garrett, et al.. (2019). The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Science Translational Medicine. 11(513). 132 indexed citations

13.

Joseph, Sarah, Laura P. Kincer, Natalie M. Bowman, et al.. (2018). Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. Clinical Infectious Diseases. 69(8). 1345–1352. 58 indexed citations

14.

Gay, Cynthia L., Mark DeBenedette, Irina Y. Tcherepanova, et al.. (2017). Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. AIDS Research and Human Retroviruses. 34(1). 111–122. 50 indexed citations

15.

Bosque, Alberto, Kyle A. Nilson, Amanda B. Macedo, et al.. (2017). Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. Cell Reports. 18(5). 1324–1334. 65 indexed citations

16.

Margolis, David M. & Nancie M. Archin. (2016). Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents. The Journal of Infectious Diseases. 215(suppl_3). S111–S118. 41 indexed citations

17.

Archin, Nancie M., Naveen K. Vaidya, JoAnn D. Kuruc, et al.. (2012). Immediate antiviral therapy appears to restrict resting CD4 ⁺ cell HIV-1 infection without accelerating the decay of latent infection. Proceedings of the National Academy of Sciences. 109(24). 9523–9528. 169 indexed citations

18.

Archin, Nancie M., Anna C. Belkina, Gerald V. Denis, et al.. (2012). BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. Journal of Leukocyte Biology. 92(6). 1147–1154. 210 indexed citations

19.

Keedy, Kara S., Nancie M. Archin, Adam Gates, et al.. (2009). A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 Expression. Journal of Virology. 83(10). 4749–4756. 163 indexed citations

20.

Archin, Nancie M., Amy S. Espeseth, Daniel Parker, et al.. (2009). Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid. AIDS Research and Human Retroviruses. 25(2). 207–212. 279 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact